How to Help Your Patients Find Dayvigo in Stock: A Provider's Guide

Helping Patients Find Dayvigo: A Practical Guide for Providers

You've prescribed Dayvigo (Lemborexant) because it's the right clinical choice for your patient's insomnia. But now they're calling back — their pharmacy doesn't have it, or their insurance denied it, or the cash price is more than they can manage. These scenarios are increasingly common, and they put providers in a difficult position between clinical best practice and real-world access barriers.

This guide gives you a practical, step-by-step framework for helping patients access Dayvigo — from checking availability to navigating insurance barriers to knowing when to pivot to alternatives. Implementing even a few of these steps can dramatically reduce the number of "I can't fill it" callbacks your office receives.

Current Availability

Let's set the baseline: Dayvigo is not in shortage. Eisai, the manufacturer, continues to produce and distribute both the 5 mg and 10 mg tablets. The drug is available through standard pharmaceutical wholesalers (McKesson, Cardinal Health, AmerisourceBergen).

The challenge is at the pharmacy level. Many retail pharmacies — particularly large chains — don't routinely stock Dayvigo because:

• Prescription volume is relatively low compared to generic sleep aids like Zolpidem
• The retail price ($400–$500/month) makes it an expensive inventory item with limited turnover
• Frequent prior authorization denials reduce successful fill rates, further discouraging stocking
• It's brand-only with no generic competition, so there's no multi-source availability
• DORA class fragmentation (three branded products) dilutes demand for any single agent

This means the medication is available in the supply chain but may not be sitting on the shelf at your patient's preferred pharmacy. For the latest availability data, see: Dayvigo Shortage: What Providers and Prescribers Need to Know in 2026.

Why Patients Can't Find It

Understanding the patient experience helps you anticipate and address their frustration. Here are the most common scenarios patients encounter:

1. Pharmacy doesn't stock it: Most chain pharmacies carry medications based on fill frequency. If a location fills fewer than 5 Dayvigo scripts per month, they may not keep it in stock. Patients often discover this only after dropping off the prescription and waiting.
2. Insurance denials: Prior authorization requirements and step therapy mandates create friction. Patients may arrive at the pharmacy only to learn their claim was denied — sometimes after waiting several days for the prescription to process.
3. Cost shock: Patients who discover the $400–$500 cash price at the pharmacy counter may abandon the prescription entirely. Without advance warning about cost and available savings programs, this is a common outcome.
4. Information gap: Many patients don't know they can ask a pharmacy to order it, try a different pharmacy, or access savings programs. They assume "they don't have it" means "it's unavailable" rather than "this location doesn't stock it."
5. Multiple barriers stacking: A patient may face insurance denial AND pharmacy unavailability simultaneously, compounding frustration and delaying treatment.

What Providers Can Do: 5 Steps

Step 1: Check Availability Before the Patient Leaves

Use Medfinder for Providers to check which pharmacies in your patient's area currently have Dayvigo in stock. This takes seconds and can save your patient hours of frustration — and save your office a callback.

Consider making this part of your standard workflow when prescribing any brand-name or niche medication. Your front desk or MA can run the search while the patient is still in the office. If no nearby pharmacy stocks it, you can proactively discuss alternatives or special-ordering with the patient before they leave.

Implementation tip: Bookmark Medfinder on office workstations and include an availability check as a line item on your prescribing checklist for brand-name medications.

Step 2: Initiate Prior Authorization Proactively

Don't wait for the pharmacy to send a PA request. If you know the patient's plan requires prior authorization (most do for Dayvigo), start the process at the time of prescribing. This can shave days off the timeline. Key documentation to include:

• Diagnosis of insomnia (ICD-10: G47.00 for unspecified, G47.01 for sleep onset, G47.09 for other)
• Prior medication trials and outcomes (e.g., "Patient tried Zolpidem 10 mg for 30 days without adequate response" or "Patient experienced complex sleep behaviors on Zolpidem")
• Clinical rationale for DORA therapy (e.g., concern for dependence with Z-drugs, elderly patient at fall risk, comorbid substance use disorder)
• Any relevant sleep study results or validated sleep questionnaire scores (ISI, PSQI)
• Documentation of comorbidities that support DORA selection over alternatives

Pro tip: Many EHR systems support PA templates. Build a Dayvigo-specific template with standard language and required clinical elements to streamline future submissions.

Step 3: Provide Savings Information at Point of Prescribing

Cost is one of the top reasons patients don't fill prescriptions. The phenomenon — known as prescription abandonment — is particularly common with high-cost brand medications. Proactively sharing savings resources can dramatically improve fill rates:

• Eisai Instant Savings Card: Reduces copay to as low as $10 for commercially insured patients. Available at dayvigo.com/prescription-savings. Valid for up to 12 uses per year.
• GoodRx / SingleCare coupons: Can bring the cash price from ~$450 down to ~$135. These are free and available online.
• Eisai Patient Assistance Program: Provides Dayvigo at no cost for eligible uninsured or underinsured patients. Application may require prescriber involvement.

Have printed or digital materials available in exam rooms or at checkout. Consider creating a one-page handout with QR codes linking to each savings program. You can direct patients to: How to Save Money on Dayvigo in 2026.

Step 4: Route the Prescription Strategically

Where you send the prescription matters more than most providers realize:

• Independent pharmacies: More likely to stock brand-name medications or order them quickly. They often have more flexible inventory practices and can frequently obtain Dayvigo within 24 hours.
• Specialty pharmacies: Some insurance plans require or prefer specialty pharmacies for brand-name controlled substances. Check the patient's plan before prescribing to avoid a routing issue.
• Mail-order pharmacies: Your patient's plan may offer 90-day mail-order with better availability and potentially lower copays. This also ensures consistent supply and eliminates repeated pharmacy visits.
• Hospital outpatient pharmacies: If your practice is affiliated with a hospital system, their outpatient pharmacy may stock a wider range of brand-name medications.
• Avoid sending to a pharmacy you know won't have it: A quick Medfinder check prevents the most common frustration point.

Step 5: Educate Patients on Self-Advocacy

Empower your patients with practical next steps if they encounter barriers. Consider providing this information verbally and in writing:

• They can ask any pharmacy to special-order Dayvigo (usually arrives in 1–3 business days)
• They should use Medfinder to check availability before going to a pharmacy
• They can call Eisai's support line (1-800-657-7613) for help with access and financial assistance
• They should not go without sleep medication — if Dayvigo is unavailable, they should call your office to discuss next steps rather than simply going without treatment
• Insurance denials can be appealed — encourage patients to ask your office for help with the appeal process

Managing the Prior Authorization Process

PA management is arguably the most impactful step providers can take. Here's a more detailed framework:

Initial Submission

Submit the PA at the time of prescribing with complete documentation. Incomplete submissions are the #1 cause of delays and denials.

Tracking and Follow-Up

Designate a staff member to track PA status. Most payers respond within 48–72 hours. If no response within the plan's required timeframe, escalate.

Handling Denials

If denied, review the denial reason carefully. Common denial reasons and responses:

• "Step therapy not completed": Document prior medication trials. If the patient has tried and failed a generic, submit that evidence.
• "Not medically necessary": Provide additional clinical rationale, sleep study data, and comorbidity documentation.
• "Preferred alternative available": Explain why the preferred alternative is not appropriate for this specific patient.

Most initially denied PAs are approved on appeal with additional documentation. Don't give up after the first denial.

Alternatives to Consider

If a patient truly cannot access Dayvigo, these alternatives maintain clinical alignment:

Within the DORA Class

• Belsomra (Suvorexant): 5, 10, 15, or 20 mg. FDA-approved since 2014. Similar mechanism with more dose flexibility. May have different formulary placement that could ease access.
• Quviviq (Daridorexant): 25 or 50 mg. Shorter half-life may reduce next-day somnolence. FDA-approved since 2022. Growing clinical experience.

Outside the DORA Class

• Zolpidem (generic Ambien): Widely available, inexpensive ($5–$20/month). IR and ER formulations. Higher abuse potential and complex sleep behavior risk. Often required as step therapy before DORA approval.
• Eszopiclone (generic Lunesta): Approved for long-term use. Inexpensive generic. Common side effect: metallic taste. Good option for patients needing ongoing therapy.
• Low-dose Doxepin (Silenor): Histamine antagonist. Particularly useful for sleep maintenance in elderly patients. Available as generic. Favorable safety profile in older adults.
• Trazodone (off-label): Widely prescribed off-label for insomnia. Very inexpensive. Sedating antidepressant mechanism. Useful for patients with comorbid depression.

For patient-facing alternatives content to share: Alternatives to Dayvigo If You Can't Fill Your Prescription.

Workflow Integration Tips

Integrating these steps into your existing workflow doesn't have to be burdensome. Here are practical suggestions:

• Build a "brand-name prescribing" checklist: Availability check → PA initiation → savings card → preferred pharmacy routing. Post it in prescribing areas.
• Train your MA or front desk: Medfinder searches and savings card enrollment can be delegated to support staff, keeping provider time focused on clinical decisions.
• Keep savings materials on hand: Print the Eisai savings card QR code or have the URL bookmarked on office computers. Create a patient handout with all savings options.
• Flag Dayvigo patients for follow-up: A quick 48-hour follow-up call to confirm the prescription was filled can catch issues early — before the patient has gone days without sleep treatment.
• Document PA denials systematically: This creates a record for appeals, helps demonstrate medical necessity patterns, and informs future prescribing decisions.
• Create EHR smart phrases: Build templates for PA letters, clinical rationale documentation, and patient education materials to save time on repeat prescribing.

Final Thoughts

Prescribing Dayvigo is the clinical decision. Helping patients actually get it filled is the access challenge — and it's a challenge that increasingly falls on provider practices to manage. With proactive PA management, strategic pharmacy routing, awareness of savings programs, and tools like Medfinder for Providers, you can significantly reduce the friction your patients experience.

The goal is simple: if Dayvigo is the right medication, let's make sure the patient actually gets it. For the current supply and availability picture, see: Dayvigo Shortage: What Providers and Prescribers Need to Know in 2026.